Regenxbio Inc (RGNX)
Solvency ratios
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.84 | 1.61 | 1.46 | 1.87 | 1.11 |
Regenxbio Inc has consistently maintained a very strong solvency position over the past five years, as indicated by its consistently low debt-to-assets, debt-to-capital, and debt-to-equity ratios, all of which were 0.00 each year. This suggests that the company has either no debt or very minimal debt compared to its assets, capital, and equity, indicating a low level of financial risk and a high level of financial stability.
However, it is worth noting that the financial leverage ratio has fluctuated over the years, with a peak of 1.87 in 2020 and a low of 1.11 in 2019. The financial leverage ratio measures the extent to which a company relies on debt to finance its operations, with a lower ratio indicating a lower reliance on debt. Regenxbio Inc's fluctuating financial leverage ratio may reflect variations in its capital structure and financing decisions during this period.
Overall, the consistently low debt-related solvency ratios coupled with fluctuating financial leverage suggest that Regenxbio Inc has maintained a prudent approach to managing its capital structure and financial risks while ensuring a strong financial position.
Coverage ratios
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Interest coverage | -37.42 | -11.06 | 6.38 | -136.50 | -1.39 |
Regenxbio Inc's interest coverage ratio has been fluctuating significantly over the years. In 2021, the company had an interest coverage ratio of 6.26, indicating that it was able to cover its interest expenses more than six times with its operating income. However, the ratio dropped substantially in 2022 to -11.47, suggesting that the company's operating income was not sufficient to cover its interest expenses. The situation further deteriorated in 2023, with an interest coverage ratio of -39.22, indicating a significant inability to cover interest payments with operating income. It is essential for Regenxbio Inc to monitor and manage its interest coverage ratio closely to ensure it maintains the ability to meet its interest obligations and avoid financial distress.